The expression of ERα usually increases both levels of Bmi1 and cyclin D1, while loss of ERα-coupled Bmi1 activity may result in aberrant p16INK4a expression and is also generally consistent with a more aggressive breast cancer phenotype. This evidence concerns the gene CDKN2A and breast cancer.